Free Trial
→ Trump's about to unleash his Midterm Weapon (From Monument Traders Alliance) (Ad)tc pixel
NASDAQ:PULM

Pulmatrix Q3 2026 Earnings Date & Estimates

Pulmatrix logo
$1.36 -0.02 (-1.09%)
As of 02:23 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Pulmatrix is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for November 9, 2026 at 9:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
9:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Pulmatrix in Q3 2026

Pulmatrix is expected to post earnings of -$2.00 per share on revenue of $1.53 million. In the same quarter a year earlier Pulmatrix reported -$0.24 per share. Pulmatrix last reported on August 13, 2026, posting -$0.29 per share and beating the -$2.00 consensus estimate.

Consensus Estimates

Consensus EPS
-$2.00
Expected Revenue
$1.53 million
Prior-Year EPS
-$0.24

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.29 (Beat by +$1.71)

Prepare for the Q3 2026 Call

Pulmatrix Q3 2026 Earnings FAQ

Pulmatrix (NASDAQ:PULM) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Pulmatrix's Q3 2026 earnings conference call is scheduled for Monday, November 9, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Pulmatrix to post earnings of -$2.00 per share for Q3 2026.

The consensus revenue estimate for Pulmatrix is $1.53 million for Q3 2026.

Pulmatrix Earnings Headlines

Pulmatrix (NASDAQ:PULM) Share Price Breaks Below 50 Day Moving Average - Here's Why
October 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31095229
Eos SENOLYTIX to Highlight Next-Generation Mitochondria-Targeted Therapeutics at 17th World Congress on Targeting Mitochondria
September 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/22/3366344/0/en/eos-senolytix-to-highlight-next-generation-mitochondria-targeted-therapeutics-at-17th-world-congress-on-targeting-mitochondria.html
Elon's next millionaires start October 24?
SpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into millionaires. One welder's $10,000 stock package made him a millionaire on IPO day. Former Wall Street CEO Dylan Jovine says Elon Musk's next venture could outsize everything he's built before. It runs on an obscure AI firm Musk has relied on since 2012, supplying crucial technology to Tesla, Starlink and SpaceX.tc pixel
October 14 at 1:00 AM  |  Behind the Markets (Ad)
Pulmatrix Inc.: Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger
August 13, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69303742-pulmatrix-inc-pulmatrix-announces-second-quarter-2026-financial-results-and-progress-on-merger-008.htm
Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger
August 13, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/pulmatrix-announces-second-quarter-2026-financial-results-and-progress-on-merger-302850250.html
Pulmatrix Stock Short Interest Report | NASDAQ:PULM | Benzinga
July 1, 2026  |  benzinga.comhttps://www.benzinga.com/quote/PULM/short-interest
See More Pulmatrix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pulmatrix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pulmatrix and other key companies, straight to your email.

About Pulmatrix

Pulmatrix (NASDAQ:PULM) (NASDAQ:PULM) is a clinical-stage biopharmaceutical company developing inhaled therapies for respiratory and other diseases. The company’s programs are based on its proprietary iSPERSE dry-powder delivery technology, which is designed to improve the delivery of drug particles to the lungs through a portable inhalation device.

Pulmatrix’s development pipeline has included PUR310, an inhaled formulation of dihydroergotamine intended for the acute treatment of migraine, as well as inhaled therapies aimed at respiratory conditions such as asthma and chronic pulmonary diseases. The company has also evaluated inhaled antifungal treatments, including programs involving itraconazole for pulmonary aspergillosis. Product candidates remain subject to clinical development and regulatory review, and their availability may depend on the results of those processes.

Founded in 2003 and headquartered in Lexington, Massachusetts, Pulmatrix has focused primarily on developing therapies for patients in the United States and other markets where its products may ultimately receive regulatory approval. As a development-stage company, Pulmatrix’s activities have centered on research, clinical trials, intellectual-property development, and potential partnerships rather than the operation of a broad commercial product portfolio.

View Pulmatrix Profile
Earnings Tools